Form SD ALCON INC
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
SPECIALIZED DISCLOSURE REPORT
Alcon Inc.
(Exact name of the registrant as specified in its charter)
Switzerland | 001-31269 | |||||||||||||||||||||||||
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | |||||||||||||||||||||||||
Rue Louis-d'Affry 6, 1701 Fribourg, Switzerland
(Address of principal executive offices)
Royce Bedward
Senior Vice President, General Counsel & Corporate Secretary
Chemin de Blandonnet 8, 1214 Vernier, Geneva, Switzerland
Tel: +41 58 911 20 00
(Name and telephone number, including area code, of the
person to contact in connection with this report.)
Check the appropriate box to indicate the rule pursuant to which this form is being filed:
_X_ Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2025.
___ Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ______.
Section 1. Conflict Minerals Disclosure
Item 1.01 Conflict Minerals Disclosure and Report
In accordance with Rule 13p-1 under the Securities Exchange Act of 1934, Alcon Inc. has filed this Specialized Disclosure Form (Form SD) and the associated Conflict Minerals Report. Both reports are posted and publicly available at the Alcon corporate website: https://www.alcon.com/about-us/commitment-integrity-and-compliance/
Item 1.02 Exhibit
The Conflict Minerals Report is attached as Exhibit 1.01.
Section 2. Resource Extraction Issuer Disclosure
Item 2.01 Resource Extraction Issuer Disclosure and Report
Not applicable.
Section 3. Exhibits
Item 3.01 Exhibits
Exhibit No. Description
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
ALCON INC. | ||||||||||||||
Date: | May 15, 2026 | By: | /s/ Timothy C. Stonesifer | |||||||||||
Name: Timothy C. Stonesifer | ||||||||||||||
Title: Authorized Representative | ||||||||||||||
Date: | May 15, 2026 | By: | /s/ Tom Hudnall | |||||||||||
Name: Tom Hudnall | ||||||||||||||
Title: Authorized Representative | ||||||||||||||
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aurion Biotech to Highlight Momentum Across Upcoming Eye Bank and Ophthalmology Meetings in June
- Chapters Health System Named as a 2026 Top Workplace for Nursing
- Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT® (sibeprenlimab-szsi) Preserved Kidney Function Over 12 Months in IgA Nephropathy (IgAN)
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share